Schizophrenia: Clinical Trials

51 trials for Schizophrenia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

51 terminated. 51 Phase 2, 8 Phase 3, 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 251Terminated 51
Phase 38Terminated 8
Phase 14Terminated 4

Follow Schizophrenia: new trials by email Literature Review of Schizophrenia trials Research Report on Schizophrenia

Trials (filtered) newest first · largest first

All 51 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia
Emraclidine 30 mg - Schizophrenia
Phase 2TerminatedAbbVie6982022-09-012026-08-21
Sodium Nitroprusside in Early Course Schizophrenia
Sodium Nitroprusside, 5% Dextrose solution - Schizophrenia, Schizoaffective Disorder
Phase 2TerminatedBeth Israel Deaconess Medical Center12022-03-142025-12-30
Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia
Placebo, Luvadaxistat - Schizophrenia
Phase 2TerminatedNeurocrine Biosciences2162021-12-072025-07-02
A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase
SEP-363856 50 mg, SEP-363856 75 mg, Placebo - Schizophrenia
Phase 2 / Phase 3TerminatedSumitomo Pharma Co., Ltd.832021-03-292024-03-15
Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment
GWP42003-P, Placebo - Schizophrenia
Phase 2TerminatedJazz Pharmaceuticals952020-08-182023-06-15
Pharmacologic Modulation of Hippocampal Activity in Psychosis
Levetiracetam 500 mg - Schizophrenia; Psychosis
Phase 2TerminatedVanderbilt University Medical Center12020-05-112021-08-05
A Pharmaco-imaging Approach to Predicting Social Functioning and Clinical Responses to Oxytocin Administration in Schizophrenia
Oxytocin, Placebo - Schizophrenia
Phase 2TerminatedVA Office of Research and Development262020-01-132026-01-20
Flexible-dose Long-term Extension Study of Lu AF11167 in Patients With Schizophrenia With Prominent Negative Symptoms
Lu AF11167 - Schizophrenia
Phase 2TerminatedH. Lundbeck A/S962019-04-222020-09-23
ITI-007 (Lumateperone Tosylate) for Schizophrenia
ITI-007 - Schizophrenia
Phase 2TerminatedNew York State Psychiatric Institute42019-03-012021-11-04
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia
Placebo, AVP-786 - Schizophrenia
Phase 2 / Phase 3TerminatedOtsuka Pharmaceutical Development & Commercialization, Inc.1362019-02-152026-09-29
Telmisartan Pilot Study on Treatment Resistant Schizophrenia
Telmisartan Pill - Schizophrenia, Schizo Affective Disorder
Phase 2TerminatedXiaoduo Fan62019-02-012022-03-02
Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With Schizophrenia
Lu AF11167 (1-2 mg/day), Lu AF11167 (3-4 mg/day), Placebo - Schizophrenia
Phase 2TerminatedH. Lundbeck A/S1682018-12-272020-09-23
A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
RO6889450, Placebo - Schizophrenia, Schizoaffective Disorder
Phase 2TerminatedHoffmann-La Roche1312018-12-042024-08-12
Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People With Schizophrenia
WSE, Placebo Oral Tablet - Schizophrenia
Phase 2 / Phase 3TerminatedChengappa, K.N. Roy, MD472018-12-012024-10-08
The Norwegian Prednisolone in Early Psychosis Study
Prednisolone, Placebo - Schizophrenia and Related Disorders, Immune Suppression
Phase 2TerminatedHaukeland University Hospital122018-02-022022-08-01
This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months
BI 409306, Placebo - Schizophrenia
Phase 2TerminatedBoehringer Ingelheim2642017-12-072025-05-14
Naltrexone-Bupropion Versus Placebo-Bupropion for Weight Loss in Schizophrenia
Naltrexone, Bupropion, Placebo - Schizophrenia, Diabetes Mellitus, Type 2
Phase 2TerminatedYale University52017-06-012019-08-07
Study to Evaluate Safety & Efficacy of NaBen® as Add-on Treatment for Schizophrenia in Adults
NaBen®, Placebo - Schizophrenia
Phase 2 / Phase 3TerminatedSyneuRx International (Taiwan) Corp2802017-03-292024-05-24
A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic Patients
Cannabidiol, Olanzapine, Placebo Cannabidiol - Schizophrenia
Phase 2TerminatedCentral Institute of Mental Health, Mannheim1502015-12-082024-12-27
A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry
Aripiprazole, Olanzapine, Paliperidone - Schizophrenia, Schizoaffective Disorder
Phase 2TerminatedJanssen Research & Development, LLC92015-05-012017-03-29

Showing 20 of 51. Sign in to see all of them.

Narrower conditions

Psychotic Disorders (12)  ·  Cognitive Dysfunction (3)  ·  Obesity (3)  ·  Cognition Disorders (2)  ·  Marijuana Abuse (2)  ·  Mental Disorders (2)  ·  Diabetes Mellitus (1)  ·  Diabetes Mellitus, Type 2 (1)  ·  Hypertension (1)  ·  Memory Disorders (1)  ·  Schizophrenia Spectrum and Other Psychotic Disorders (1)  ·  Schizophrenia, Childhood (1)  ·  Schizophrenia, Treatment-Resistant (1)  ·  Smoking (1)

Broader conditions

Schizophrenia Spectrum and Other Psychotic Disorders (50)  ·  Mental Disorders (49)  ·  Neurocognitive Disorders (5)  ·  Pathological Conditions, Signs and Symptoms (5)  ·  Signs and Symptoms (5)  ·  Body Weight (3)  ·  Cognition Disorders (3)  ·  Nutrition Disorders (3)  ·  Nutritional and Metabolic Diseases (3)  ·  Overnutrition (3)  ·  Overweight (3)  ·  Chemically-Induced Disorders (2)  ·  Nervous System Diseases (2)  ·  Neurologic Manifestations (2)  ·  Substance-Related Disorders (2)

Interventions

Olanzapine (4)  ·  Risperidone (3)  ·  (R)-2-(4-(phenyl(3-(trifluoromethyl)phenyl)methyl)piperazin-1-yl)acetic acid (2)  ·  2-((4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy)methyl)quinoline (2)  ·  Aripiprazole (2)  ·  Dronabinol (2)  ·  LY 2140023 (2)  ·  Quetiapine Fumarate (2)  ·  1-methyl-1H-imidazole-4-carboxylic acid (3-chloro-4-fluoro-benzyl)-(3-methyl-3-aza-bicyclo(3.1.0) hex-6-ylmethyl)amide (1)  ·  ABT-126 (1)  ·  ABT-925 (1)  ·  AVE1625 (1)  ·  Ashwagandha (1)  ·  Atomoxetine Hydrochloride (1)  ·  BI 409306 (1)

Sponsors

National Institute of Mental Health (NIMH) (3)  ·  Pfizer (3)  ·  AbbVie (2)  ·  Amgen (2)  ·  Denovo Biopharma LLC (2)  ·  H. Lundbeck A/S (2)  ·  New York State Psychiatric Institute (2)  ·  SyneuRx International (Taiwan) Corp (2)  ·  Abbott (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  AstraZeneca (1)  ·  Beth Israel Deaconess Medical Center (1)  ·  BioLineRx, Ltd. (1)  ·  Birte Glenthoj (1)  ·  Boehringer Ingelheim (1)

Countries

United States (38)  ·  Bulgaria (5)  ·  Canada (5)  ·  Japan (5)  ·  Poland (5)  ·  Spain (5)  ·  Taiwan (5)  ·  Ukraine (5)  ·  Czechia (3)  ·  France (3)  ·  Germany (3)  ·  Hungary (3)  ·  Puerto Rico (3)  ·  Russia (3)  ·  South Korea (3)

Top investigators

Alan Breier, MD (2)  ·  Jose A Apud, M.D. (2)  ·  Andrew Cutler, MD (1)  ·  Arielle D. Stanford, MD (1)  ·  Arnon Aharon, MD (1)  ·  Beatrice Rendenbach-Mueller, PhD (1)  ·  Birte Glenthoj, MD, DMSc. (1)  ·  Brian A Fallon, MD (1)

Results publications

PMID 27789188, PMID 28433500, PMID 35704951, PMID 21346607, PMID 23794107, PMID 25554563, PMID 25890643, PMID 26493637, PMID 27319970, PMID 28705532, PMID 32513294, PMID 36369028, PMID 39637767, PMID 42032293

NIH funding

2017 (1), 2019 (1), I01CX001761 (1)